Brain distribution and kinetics of 11C-chlorpromazine in schizophrenics: Positron emission tomography studies

Comar, D.; Zarifian, E.; Verhas, Michel; Soussaline, F.; Mazière, M.; Berger, G.; Lôo, Henri; Cuché, H; Kellershohn, C.; Deniker, P

doi:10.1016/0165-1781(79)90024-6

Cited by 53 publications

(21 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Imaging with radiolabeled dopamine receptor ligands added a powerful tool to the study of dopamine receptors in psychotic disorders, but also highlighted the importance of each ligand’s pharmacodynamic properties in defining the scope of testable hypotheses. The earliest study with radiolabeled chlorpromazine(Comar et al, 1979) showed cortical distribution abnormalities probably attributable to blood flow. Studies in the 1980’s and 1990’s using tracers such as 11 C-raclopride(Farde et al, 1990) and 11 C-methylspiperone(Wong et al, 1986) were by and large limited to examinations of the striatum and were inconsistent, although large studies(Tune et al, 1993) confirmed striatal abnormalities (see also reviews by Andreasen et al (1988)).…”

Section: Introductionmentioning

confidence: 99%

18F-Fallypride binding potential in patients with schizophrenia compared to healthy controls

Lehrer

Christian

Kirbas

et al. 2010

Schizophrenia Research

View full text Add to dashboard Cite

Background Molecular imaging of dopaminergic parameters has contributed to the dopamine hypothesis of schizophrenia, expanding our understanding of pathophysiology, clinical phenomenology and treatment. Our aim in this study was to compare 18F-fallypride binding potential BPND in a group of patients with schizophrenia-spectrum illness vs. controls, with a particular focus on the cortex and thalamus. Methods We acquired 18F-fallypride positron emission tomography images on 33 patients with schizophrenia spectrum disorder (28 with schizophrenia; 5 with schizoaffective disorder) and 18 normal controls. Twenty-four patients were absolutely neuroleptic naïve and nine were previously medicated, although only four had a lifetime neuroleptic exposure of greater than two weeks. Parametric images of 18F-fallypride BPND were calculated to compare binding across subjects. Results Decreased BPND was observed in the medial dorsal nucleus of the thalamus, prefrontal cortex, lateral temporal lobe and primary auditory cortex. These findings were most marked in subjects who had never previously received medication. Conclusions The regions with decreased BPND tend to match brain regions previously reported to show alterations in metabolic activity and blood flow and areas associated with the symptoms of schizophrenia.

show abstract

Section: Introductionmentioning

confidence: 99%

18F-Fallypride binding potential in patients with schizophrenia compared to healthy controls

Lehrer

Christian

Kirbas

et al. 2010

Schizophrenia Research

View full text Add to dashboard Cite

show abstract

“…Remotely controlled synthesis systems for several carbon-11 compounds were also being developed around the same time (Berger et al, 1979;Padgett et al, 1982;Welch et al, 1982;Welch et al, 1983). Although sometimes referred to as "automated" systems (Berger et al, 1979), these carbon-11 synthesis systems used devices controlled remotely by a human operator in a fashion similar to that described above for the synthesis of FDG (Fowler et al, 1981).…”

Section: Automation Of Radiotracer Synthesismentioning

confidence: 99%

“…Unit operations design was first successfully applied to the design of remotely controlled syntheses of several 1lC (Berger 1979;Welch et al, 1982;Padgett, et al, 1982) and 18F labeled compounds including FDG (Barrio et al, 1981;Fowler et al, 1981). This modular approach to remote apparatus construction has a parallel application to the design of automated equipment and computer software (Alexoff et al, 1986;Felieu 1991;Russell et al, 1987).…”

Section: Unit Operations Designmentioning

confidence: 99%

“…The development of automateds ystems supporting the production and application of PET radiopharmaceuticals has been an important focus of researchers since the first successes of using carbon-11 (Comar et al, 1979) and fluorine-18 (Reivich et al, 1979) labeled compounds to visualize functional activity of the human brain. These initial successes of imaging the human brain soon led to applications in the human heart (Schelbert et al, 1980), and quickly radiochemists began to see the importance of automation to support PET studies in humans (Lambrecht,1982;Langstrom et al, 1983).…”

Section: Introductionmentioning

confidence: 99%

“…

IntroductionThe development of automateds ystems supporting the production and application of PET radiopharmaceuticals has been an important focus of researchers since the first successes of using carbon-11 (Comar et al, 1979) and fluorine-18 (Reivich et al, 1979) labeled compounds to visualize functional activity of the human brain. These initial successes of imaging the human brain soon led to applications in the human heart (Schelbert et al, 1980), and quickly radiochemists began to see the importance of automation to support PET studies in humans (Lambrecht,1982;Langstrom et al, 1983).

Driven by the necessity of controlling processes emanating high fluxes of 51 lKeV photons, and by the tedium of repetitive syntheses for carrying out these human PET investigations, academic and government scientists have designed, developed and tested many useful and novel automated systems in the past twenty years.

…”

mentioning

confidence: 99%

See 2 more Smart Citations

Automation for the Synthesis and Application of PET Radiopharmaceuticals

Alexoff

2002

Handbook of Radiopharmaceuticals

View full text Add to dashboard Cite

These unique constraints include short synthesis (often limited to20r3 half-lives) times and control from behind bulky shielding structures that make both access to, and visibility of, radiochemical processes and equipment difficult. Often Curie levels of positron emitting nuclides are required for synthesis of PET radiopharmaceuticals, making this potentially dangerous for a radiochemist or laboratory specialist. The use of short half-lived radionuclides also necessitates that many PET radiotracers (particularly those labeled with 1lC, *3N, and '50) be synthesized repetitively during the day, each dose being produced separately just before administration.Radiotracer synthesis must be reliable and efficient to keep the costs of PET procedures down. Furthermore, radiotracer synthesis procedures for human use must produce pharmaceutical quality products and be well documented and controlled to help satisfy requirements of federal and local regulations on human research.Automation can help PET research institutions overcome all of these potential '" limitations. A look at the history of the development of successful automated PET radiotracer synthesis machines reveals a richness in engineering solutions to these problems that still exists today.

show abstract

Automation of PET Radiopharmaceutical Quality Control

Elizarov

2020

Handbook of Radiopharmaceuticals

View full text Add to dashboard Cite

Brain distribution and kinetics of 11C-chlorpromazine in schizophrenics: Positron emission tomography studies

Cited by 53 publications

References 6 publications

18F-Fallypride binding potential in patients with schizophrenia compared to healthy controls

18F-Fallypride binding potential in patients with schizophrenia compared to healthy controls

Automation for the Synthesis and Application of PET Radiopharmaceuticals

Automation of PET Radiopharmaceutical Quality Control

Contact Info

Product

Resources

About